Takeda Pharmaceutical Company Limited
New York Stock ExchangeTotal Valuation
Takeda Pharmaceutical Company Limited carries a market capitalization of 47.96B, placing it among publicly traded companies globally. Its enterprise value stands at 11.74T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 47.96B |
| Enterprise Value | 11.74T |
Share Statistics
Takeda Pharmaceutical Company Limited currently has 1.58B shares outstanding.
| Shares Outstanding | 1.58B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Takeda Pharmaceutical Company Limited trades at a trailing price-to-earnings ratio of 67.71. The price-to-sales ratio is 1.71, and the price-to-book ratio stands at 2.74.
| PE Ratio | 67.71 |
| PS Ratio | 1.71 |
| PB Ratio | 2.74 |
| P/TBV Ratio | -4.71 |
| P/FCF Ratio | 4.76 |
| P/OCF Ratio | 6.43 |
Enterprise Valuation
On an enterprise value basis, Takeda Pharmaceutical Company Limited trades at an EV/EBITDA multiple of 9.48 and an EV/FCF ratio of 6.55. The EV/Sales ratio of 2.63 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 23.91 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.63 |
| EV / EBITDA | 9.48 |
| EV / EBIT | 23.91 |
| EV / FCF | 6.55 |
Financial Position
Takeda Pharmaceutical Company Limited maintains a current ratio of 1.19, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 63.49, indicating elevated leverage, while an interest coverage ratio of 4.25 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.19 |
| Quick Ratio | 0.58 |
| Debt / Equity | 63.49 |
| Debt / EBITDA | 3.92 |
| Interest Coverage | 4.25 |
Financial Efficiency
Takeda Pharmaceutical Company Limited posts a return on equity of 3.91 and a return on invested capital of 2.16.
| Return on Equity (ROE) | 3.91 |
| Return on Assets (ROA) | 0.74 |
| Return on Invested Capital (ROIC) | 2.16 |
| Return on Capital Employed (ROCE) | 3.53 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.17 |
Taxes
Over the trailing twelve months, Takeda Pharmaceutical Company Limited has paid 92.18B in income taxes, reflecting an effective tax rate of 44.89.
| Income Tax | 92.18B |
| Effective Tax Rate | 44.89 |
Stock Price Statistics
Takeda Pharmaceutical Company Limited's stock has gained approximately 1.40281% over the past 52 weeks. The 50-day moving average sits at 17.10, while the 200-day moving average is 15.98.
| Beta (5Y) | N/A |
| 52-Week Price Change | 1.40281% |
| 50-Day Moving Average | 17.10 |
| 200-Day Moving Average | 15.98 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Takeda Pharmaceutical Company Limited generated 4.46T in revenue and converted that into 112.93B in net income, yielding earnings per share of 35.63. EBITDA reached 1.24T, while operating income came in at 490.93B.
| Revenue | 4.46T |
| Gross Profit | 2.92T |
| Operating Income | 490.93B |
| Pretax Income | 205.37B |
| Net Income | 112.93B |
| EBITDA | 1.24T |
| EBIT | 490.93B |
| Earnings Per Share (EPS) | 35.63 |
Balance Sheet
Takeda Pharmaceutical Company Limited holds 761.94B in cash and equivalents against 4.85T in total debt, resulting in a net debt position of 4.20T. Total book value stands at 2.79T, with working capital of 506.26B providing operational flexibility.
| Cash & Cash Equivalents | 761.94B |
| Total Debt | 4.85T |
| Net Debt | 4.20T |
| Equity (Book Value) | 2.79T |
| Book Value Per Share | 891.66 |
| Working Capital | 506.26B |
Cash Flow
Takeda Pharmaceutical Company Limited produced 1.19T in operating cash flow over the past twelve months. After subtracting -442.99B in capital expenditures, free cash flow totaled 746.07B - equivalent to 238.40 per share.
| Operating Cash Flow | 1.19T |
| Capital Expenditures | -442.99B |
| Free Cash Flow | 746.07B |
| FCF Per Share | 238.40 |
Margins
Takeda Pharmaceutical Company Limited operates with a gross margin of 65.33, reflecting its pricing power and cost economics. The operating margin of 11.00 and net profit margin of 2.53 provide insight into operational efficiency.
| Gross Margin | 65.33 |
| Operating Margin | 11.00 |
| Pretax Margin | 4.60 |
| Profit Margin | 2.53 |
| EBITDA Margin | 27.73 |
Dividends & Yields
The company's payout ratio of 275.78 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 99.97 |
| Dividend Yield | N/A |
| Payout Ratio | 275.78 |
| Shareholder Yield | 9.43 |
| FCF Yield | 21.03 |
Scores
Takeda Pharmaceutical Company Limited posts an Altman Z-Score of 1.93, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.93 |